Register for Event

Please view the discount options for courses before registering here.

  • Intro to Biotech Package Member: $1,550 

  • Intro to Biotech Package Non-Member: 1,800

  • Member Rate: $850

  • Non-Member Rate: $1,025

Description

The Intro to Biotech course is divided into two parts: Intro to Business and Intro to Science. We provide a significant discount when individuals take the course as a package. While you can choose to attend one or the other, we highly recommend taking the course as a package to learn a more in-depth understanding of the biotech world.

Intro to Business explore considerations that drive company strategies. Students will be provided with foundational information about the biopharma industry and regulation via instruction, storytelling, and small group discussions. Industry ethics will be discussed, with emphasis on historical precedents. The course touches on topics such as market share, phases of development, patient population, safety profile, and more.

Date & Time

Intro to Business:

  1. Monday, December 9th, 2024, 09:00 AM-11:30 AM EST
  2. Wednesday, December 11th, 2024, 09:00 AM-11:30 AM EST
  3. Thursday, December 12th, 2024, 09:00 AM-11:30 AM EST

Click here for the Intro to Science schedule (only attend if you are also registered to take the Science class)

Instructors

John Tagliamonte
Chief Executive Officer, Mellitus

John Tagliamonte has more than 30 years of experience in executive leadership with responsibility for business development, finance, commercial and business operations, strategic planning, finance and legal functions with established and emerging public and private life sciences companies.  As the first Entrepreneur-in-Residence with MassBio, he was responsible for forward-looking program content across the organization, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx, Fractal, MarkTx, PhagePro and Tantu.  Previously he led business development at Juniper, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics, ImmunoGen and Johnson & Johnson, as well as venture investing with Safeguard.  He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad.  Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University.

Atul Deshpande, Ph.D., MBA
Chief Strategy Officer, Peptilogics

Atul Deshpande is the Chief Strategy Officer at Peptilogics, a clinical stage AI/ML driven peptide therapeutics company, where he is responsible for corporate strategy and business development. Prior to that he was the Chief Executive Officer of IMMEDIATE Therapeutics, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS), the most common cause of death and morbidity across the world. Atul spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi, Atul worked as a management consultant for 9 years on projects across the value chain of pharma. Atul holds a Ph.D. from UC Irvine in Neuroscience and a post-doc from UCLA.